AMGN compared with RXRX: revenue, margins and what each company keeps, and the suppliers and customers both name

AMGNAmgen Inc

Mkt capRevenueRevenue

RXRXRecursion Pharmaceuticals, Inc.

Mkt capRevenueRevenue

Compare

AMGNAmgen Inc

RXRXRecursion Pharmaceuticals, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

AMGN

4 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±4.1%▲+4.57%×1.12

Q1 FY26±3.9%▼−4.75%×1.23

Feb 4 '26±3.7%▲+8.15%×2.22

Q3 FY25±3.7%▲+7.81%×2.11

RXRX

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±14.1%▼−4.23%×0.30

May 6 '26±8.9%▲+1.78%×0.20

= impliedAMGN realized, solidRXRX realized, hatchedOne scale, both sides: full bar = 15%× = |realized| ÷ impliedSource: market data

Q1 FY26

±8.4%

▲+6.80%

×0.81

Q3 FY25±11.1%▼−0.80%×0.07

AMGNAmgen Inc

465.45▼−0.12%· post 466.36

Mkt cap$251.6BRevenue$10.1BQ2 FY26Revenue$36.8BFY25

RXRXRecursion Pharmaceuticals, Inc.

3.81▼−5.46%· post 3.83

ClosedNov 2 '26

Mkt cap$2.2BRevenue$19MQ3 FY26Revenue$75MFY25

Compare

ClosedNov 2 '26

AMGNAmgen Inc

RXRXRecursion Pharmaceuticals, Inc.

465.45▼−0.12%post 466.36

Price

3.81▼−5.46%post 3.83

$251.6B

Mkt cap

$2.2B

Q2 FY26$10.1B

Revenue

$19MQ3 FY26

FY25$36.8B

Revenue

$75MFY25

AMGN465.45▼−0.12%vsRXRX3.81▼−5.46%ClosedNov 2 '26